Drug Type Trispecific killer cell engager (TriKE) |
Synonyms Trispecific NK cell engager(Ferring) |
Target |
Mechanism CD16a agonists(Low affinity immunoglobulin gamma Fc region receptor III-A agonists), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CH | 04 Apr 2023 | |
Neoplasms | Preclinical | DE | 04 Apr 2023 | |
Neoplasms | Preclinical | DE | 04 Apr 2023 |